Difference between revisions of "Oley"
(Created page with " '''<span style="font-size:18.0pt"><span style="font-family:" times="" new="" roman",serif"="">No comparisons made after treatment of crush injuries between hyperbaric oxygen...") |
|||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
| − | '''<span style="font-size:18.0pt"><span style="font-family: | + | '''<span style="font-size:18.0pt"><span style="font-family:">No comparisons made after treatment of crush injuries between hyperbaric oxygen group and control.</span></span>''' |
| − | '''<span style="font-size:14.0pt"><span style="font-family: | + | '''<span style="font-size:14.0pt"><span style="font-family:">Clinical bottom line:</span></span>''' |
| − | #<span style="font-size:14.0pt"><span style="font-family: | + | #<span style="font-size:14.0pt"><span style="font-family:">No outcomes was assessed between groups after institution of HBO compared to control.</span></span> |
| + | |||
| + | <span style="font-size:larger;">'''<span style="font-family:">Citation/s:</span>'''<span style="font-family:">1. Oley MH, Oley MC, Noersasongko AD, Hatta M, Philips GG, Faruk M, Kalangi JA, Rumampuk IM, Tulong MT. Effects of hyperbaric oxygen therapy on vascular endothelial growth factor protein and mRNA in crush injury patients: a randomised controlled trial study. International Journal of Surgery Open. 29(2021) 33-39.</span></span> | ||
---- | ---- | ||
| − | <span style="font-size:larger;">'''<span style="font-family: | + | <span style="font-size:larger;">'''<span style="font-family:">Lead author’s name and fax:</span>'''<span style="font-family:">M. H. Oley : mendy.hatibie@unsrat.ac.id</span></span> |
| − | |||
| − | |||
| − | |||
| − | |||
| − | <span style="font-size:larger;">'''<span style="font-family: | + | <span style="font-size:larger;">'''<span style="font-family:">Three-part Clinical Question:</span>'''<span style="font-family:">In patients with crush injury, does the addition of hyperbaric oxygen to standard therapy, compared to standard therapy alone, result in increased VEGF serum and mRNA levels?</span></span> |
| − | <span style="font-size:larger;">'''<span style="font-family: | + | <span style="font-size:larger;">'''<span style="font-family:">Search Terms:</span>'''<span style="font-family:">Crush injury; vascular endothelial growth factor; wound healing</span></span> |
| − | '''<span style="font-family: | + | '''<span style="font-family:">The Study:</span>'''<span style="font-size: larger; font-family:">Non-blinded non-concealed randomised controlled trial with intention-to-treat.</span> |
| − | <span style="font-size:larger;">'''<span style="font-family: | + | <span style="font-size:larger;">'''<span style="font-family:">The Study Patients:</span>'''<span style="font-family:">Patients between 15-64 years old admitted with crush injury. Patients with contraindications to receiving HBO were excluded.</span></span> |
| − | <span style="font-size:larger;">'''<span style="font-family: | + | <span style="font-size:larger;">'''<span style="font-family:">Control group</span>'''<span style="font-family:">(N = 8; 8 analysed): Wound debridement and limb salvage surgery.</span></span> |
| − | <span style="font-size:larger;">'''<span style="font-family: | + | <span style="font-size:larger;">'''<span style="font-family:">Experimental group</span>'''<span style="font-family:">(N = 7; 7 analysed): Wound debridement and limb salvage surgery followed by HBOT 100% O2 at 2.4 ATA for 60 minutes daily for 10 consecutive days.</span></span> |
| | ||
| − | <span style="font-size:larger;">'''<span style="font-family: | + | <span style="font-size:larger;">'''<span style="font-family:">The Evidence:</span>'''</span> |
| − | <span style= | + | <span style="font-size:larger;">No comparisons made between groups after HBO course.</span> |
| | ||
| − | <span style="font-size:larger;">'''<span style="font-family: | + | <span style="font-size:larger;">'''<span style="font-family:">Comments:</span>'''</span> |
| − | #<span style="font-size:larger;"><span style="font-family: | + | #<span style="font-size:larger;"><span style="font-family:">No outcomes assessed with which to compare HBO plus standard care to standard care alone.</span></span> |
| − | #<span style="font-size:larger;"><span style="font-family: | + | #<span style="font-size:larger;"><span style="font-family:">The sample size was very small with no sample size calculation described.</span></span> |
| − | #<span style="font-size:larger;"><span style="font-family: | + | #<span style="font-size:larger;"><span style="font-family:">Follow up period was limited to 0 days in the control group and 10 days in the hyperbaric group. No long-term conclusions can be drawn.</span></span> |
| − | #<span style="font-size:larger;"><span style="font-family: | + | #<span style="font-size:larger;"><span style="font-family:"><span style="color:black">The authors’ analysis looked at serum VEGF and VEGF mRNA. It is not clear why they did not compare groups at the 10 day point.</span></span></span> |
| | ||
| − | <span style="font-size:larger;">'''<span style="font-family: | + | <span style="font-size:larger;">'''<span style="font-family:">Appraised by: </span>'''<span style="font-family:">Hannah Rubinstein h.rubinstein@student.unsw.edu.au; Monday, 6 December 2021</span></span> |
| − | + | <span style="font-size:larger;">'''Kill or Update By: '''November 2025</span> | |
| + | <p style="text-align: center;"> </p> <p style="text-align: center;">[[File:Sumhorsa.gif|center|sumhorsa.gif]]</p> | ||
| + | == <span style="font-size:xx-large;">[[Crush_injuries|BACK]]</span> == | ||
Latest revision as of 22:57, 23 August 2022
No comparisons made after treatment of crush injuries between hyperbaric oxygen group and control.
Clinical bottom line:
- No outcomes was assessed between groups after institution of HBO compared to control.
Citation/s:1. Oley MH, Oley MC, Noersasongko AD, Hatta M, Philips GG, Faruk M, Kalangi JA, Rumampuk IM, Tulong MT. Effects of hyperbaric oxygen therapy on vascular endothelial growth factor protein and mRNA in crush injury patients: a randomised controlled trial study. International Journal of Surgery Open. 29(2021) 33-39.
Lead author’s name and fax:M. H. Oley : mendy.hatibie@unsrat.ac.id
Three-part Clinical Question:In patients with crush injury, does the addition of hyperbaric oxygen to standard therapy, compared to standard therapy alone, result in increased VEGF serum and mRNA levels?
Search Terms:Crush injury; vascular endothelial growth factor; wound healing
The Study:Non-blinded non-concealed randomised controlled trial with intention-to-treat.
The Study Patients:Patients between 15-64 years old admitted with crush injury. Patients with contraindications to receiving HBO were excluded.
Control group(N = 8; 8 analysed): Wound debridement and limb salvage surgery.
Experimental group(N = 7; 7 analysed): Wound debridement and limb salvage surgery followed by HBOT 100% O2 at 2.4 ATA for 60 minutes daily for 10 consecutive days.
The Evidence:
No comparisons made between groups after HBO course.
Comments:
- No outcomes assessed with which to compare HBO plus standard care to standard care alone.
- The sample size was very small with no sample size calculation described.
- Follow up period was limited to 0 days in the control group and 10 days in the hyperbaric group. No long-term conclusions can be drawn.
- The authors’ analysis looked at serum VEGF and VEGF mRNA. It is not clear why they did not compare groups at the 10 day point.
Appraised by: Hannah Rubinstein h.rubinstein@student.unsw.edu.au; Monday, 6 December 2021
Kill or Update By: November 2025
